MCID: FLL037
MIFTS: 70

Follicular Lymphoma malady

Categories: Rare diseases, Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Follicular Lymphoma

Aliases & Descriptions for Follicular Lymphoma:

Name: Follicular Lymphoma 38 12 50 14
Lymphoma, Follicular 50 29 42 69
Lymphoma Follicular 52

Classifications:



External Ids:

Disease Ontology 12 DOID:0050873
MeSH 42 D008224
ICD10 33 C82

Summaries for Follicular Lymphoma

Disease Ontology : 12 A non-Hodgkin lymphoma that is characterized as an indolent non-Hodgkin's lymphoma and has material basis in follicle center B-cells (centrocytes and centroblasts).

MalaCards based summary : Follicular Lymphoma, also known as lymphoma, follicular, is related to follicular lymphoma 1 and primary cutaneous follicle center lymphoma, and has symptoms including fatigue, fever and night sweats. An important gene associated with Follicular Lymphoma is BCL2 (BCL2, Apoptosis Regulator), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Arzerra and Intron A have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and hematopoietic system

Wikipedia : 71 Follicular lymphoma is a type of blood cancer. It is the most common of the indolent (slow-growing)... more...

Related Diseases for Follicular Lymphoma

Diseases in the Follicular Lymphoma family:

Follicular Lymphoma 1

Diseases related to Follicular Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 145)
id Related Disease Score Top Affiliating Genes
1 follicular lymphoma 1 12.4
2 primary cutaneous follicle center lymphoma 11.2
3 lymphoma 11.0
4 histiocytic and dendritic cell cancer 10.9
5 diffuse large b-cell lymphoma 10.7
6 mantle cell lymphoma 10.6
7 primary effusion lymphoma 10.5
8 lymphoblastic lymphoma 10.4
9 plasmablastic lymphoma 10.4
10 primary central nervous system lymphoma 10.4
11 nodal marginal zone b-cell lymphoma 10.4
12 b-cell lymphomas 10.3
13 rubella panencephalitis 10.3 BCL2 BCL6
14 ichthyosis, congenital, autosomal recessive 10 10.3 BCL2 BCL6 IGH
15 coloboma of eyelid 10.3 BCL2 BCL6 MME
16 ethmoid sinus inverted papilloma 10.3 BCL6 MME
17 prinzmetal's variant angina 10.2 BCL6 IRF4 MYC
18 hyperparathyroidism, primary, caused by water clear cell hyperplasia 10.2 AICDA CD40
19 male infertility 10.2 BCL2 CCND1
20 prader-willi syndrome due to translocation 10.2 BCL6 CXCR5
21 temtamy syndrome 10.2 AICDA BCL6 CD40
22 burkitt lymphoma 10.2
23 pseudohypoaldosteronism, type iic 10.1 BCL2L1 CD27 MCL1
24 hyperphosphatasia with mental retardation syndrome 2 10.1 IGH MME MYC
25 eye disease 10.1 CD27 MME
26 polycystic bone disease 10.1 CCND1 IRF4
27 leukemia 10.1
28 lymphomatoid granulomatosis 10.1
29 duodenitis 10.1
30 ovarian wilms' cancer 10.1 CR2 MME MYC
31 carnitine-acylcarnitine translocase deficiency 10.1 BCL2 BCL6 IRF4 MS4A1
32 tall cell variant papillary carcinoma 10.1 AICDA BCL6 CD40 MME MYC
33 theileriasis 10.0 CCND1 CD27 MYC
34 thoracic outlet syndrome 10.0 BCL2 CCND1 MYC
35 sarcoma 10.0
36 microcystic adenoma 10.0 BCL2 BCL6 CCND1 IRF4 MME
37 hematopoietic stem cell transplantation 10.0
38 chronic lymphocytic leukemia 10.0
39 pemphigus 9.9
40 paraneoplastic pemphigus 9.9
41 primary cutaneous diffuse large b-cell lymphoma, leg type 9.9
42 splenic marginal zone lymphoma 9.9
43 primary cutaneous marginal zone b-cell lymphoma 9.9
44 alk-positive large b-cell lymphoma 9.9
45 epstein-barr virus-positive diffuse large b-cell lymphoma of the elderly 9.9
46 diffuse large b-cell lymphoma of the central nervous system 9.9
47 splenic diffuse red pulp small b-cell lymphoma 9.9
48 diffuse large b-cell lymphoma with chronic inflammation 9.9
49 lymphoplasmacytic lymphoma without igm production 9.9
50 leukemia, acute lymphoblastic 3 9.9

Graphical network of the top 20 diseases related to Follicular Lymphoma:



Diseases related to Follicular Lymphoma

Symptoms & Phenotypes for Follicular Lymphoma

Human phenotypes related to Follicular Lymphoma:

32 (show all 12)
id Description HPO Frequency HPO Source Accession
1 fatigue 32 HP:0012378
2 fever 32 HP:0001945
3 night sweats 32 HP:0030166
4 splenomegaly 32 HP:0001744
5 weight loss 32 HP:0001824
6 lymphedema 32 HP:0001004
7 meningitis 32 HP:0001287
8 lymphoma 32 HP:0002665
9 mediastinal lymphadenopathy 32 HP:0100721
10 abnormality of the peritoneum 32 HP:0002585
11 pleural effusion 32 HP:0002202
12 skin nodule 32 HP:0200036

GenomeRNAi Phenotypes related to Follicular Lymphoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.32 MCL1 BCL2 BCL2L1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.32 MCL1 MYC BCL2 BCL2L1 CCND1 CD27

MGI Mouse Phenotypes related to Follicular Lymphoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.86 AICDA BCL2 BCL2L1 BCL6 CCND1 CD27
2 immune system MP:0005387 9.55 CD80 CR2 CXCR5 IRF4 MCL1 MME

Drugs & Therapeutics for Follicular Lymphoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Arzerra 17 46 OFATUMUMAB GlaxoSmithKline Approved October 2009
2
Intron A 17 46 INTERFERON ALFA-2B Schering-Plough Approved December 1997/ Approved December 1995/ Approved March 1997
3
Zevalin 17 46 IBRITUMOMAB TIUXETAN Biogen IDEC Approved February 2002

Drugs for Follicular Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 535)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
3
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
4
Vidarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 24356-66-9 32326 21704
5
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
6
Thiotepa Approved Phase 4,Phase 2,Phase 3,Phase 1 52-24-4 5453
7 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
8 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
9 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
10 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
11 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
12 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1
14 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1
16 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
17
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 83-43-2 6741
18
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 50-24-8 5755
19
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
20
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
21
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
22
Chlorambucil Approved Phase 3 305-03-3 2708
23
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
24
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
25
Idarubicin Approved Phase 3 58957-92-9 42890
26
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
27
Etoposide Approved Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
28
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
29
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 4053 460612
30
Cefepime Approved Phase 3,Phase 1 88040-23-7 5479537
31
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
32
Ofloxacin Approved Phase 3 82419-36-1 4583
33
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
34
Amoxicillin Approved, Vet_approved Phase 3,Phase 2 26787-78-0 33613 2171
35
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
36
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
37
Carmustine Approved Phase 3,Phase 2,Phase 1 154-93-8 2578
38
Cytarabine Approved, Investigational Phase 3,Phase 1,Phase 2 147-94-4 6253
39
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
40
Ifosfamide Approved Phase 3,Phase 1,Phase 2,Early Phase 1 3778-73-2 3690
41
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
42
Mechlorethamine Approved Phase 3,Phase 1,Phase 2,Early Phase 1 51-75-2 4033
43
Cyclosporine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
44
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
45
Bortezomib Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 179324-69-7 387447 93860
46
Lenalidomide Approved Phase 3,Phase 2,Phase 1 191732-72-6 216326
47
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
48
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
49
Tacrolimus Approved, Investigational Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
50
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750

Interventional clinical trials:

(show top 50) (show all 1139)
id Name Status NCT ID Phase
1 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Completed NCT00430352 Phase 4
2 Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma Completed NCT01124526 Phase 4
3 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
4 Low Grade Lymphoma Recruiting NCT01698866 Phase 4
5 A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients Unknown status NCT01303887 Phase 3
6 Multicentric Study, Three Randomized Arms (R−CVP vs R−CHOP vs R−FM),for Patients With Stage II−IV Follicular Lymphoma Unknown status NCT00774826 Phase 3
7 Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma Unknown status NCT00435955 Phase 3
8 Chlorambucil Compared With Radiation Therapy in Treating Patients With Previously Untreated Stage III or Stage IV Follicular Lymphoma Unknown status NCT00028691 Phase 3
9 Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma Unknown status NCT00091676 Phase 3
10 Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP Unknown status NCT01210287 Phase 2, Phase 3
11 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Non-Hodgkin's Lymphoma Unknown status NCT00006250 Phase 3
12 Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma Unknown status NCT00017290 Phase 3
13 A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma Unknown status NCT00078598 Phase 3
14 Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma Unknown status NCT00022685 Phase 3
15 Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma Unknown status NCT00463463 Phase 3
16 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
17 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3
18 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
19 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3
20 Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00028717 Phase 3
21 Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00053768 Phase 3
22 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
23 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3
24 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
25 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
26 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3
27 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3
28 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
29 High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003578 Phase 3
30 High-Dose Therapy Treatment in Patients With Follicular Lymphoma Completed NCT00696735 Phase 3
31 Randomized Study for Patients With Follicular Lymphoma Needing Treatment Completed NCT00140569 Phase 3
32 A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma Completed NCT02569996 Phase 3
33 Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden Completed NCT00136552 Phase 3
34 Primary Rituximab and Maintenance Completed NCT00140582 Phase 3
35 Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy Completed NCT00185393 Phase 3
36 A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE) Completed NCT00719472 Phase 3
37 A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a Completed NCT01724021 Phase 3
38 A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL) Completed NCT01144364 Phase 3
39 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma Completed NCT00005589 Phase 3
40 Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma Completed NCT00268983 Phase 3
41 Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102) Completed NCT00168740 Phase 3
42 A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 Completed NCT00400478 Phase 3
43 Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00012051 Phase 3
44 Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments Completed NCT00045877 Phase 2, Phase 3
45 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma Completed NCT00003204 Phase 3
46 Bendamustine Plus Rituximab Versus CHOP Plus Rituximab Completed NCT00991211 Phase 3
47 Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3
48 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
49 Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma Completed NCT00002565 Phase 3
50 Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Completed NCT00005867 Phase 3

Search NIH Clinical Center for Follicular Lymphoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Follicular Lymphoma cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lymphoma, follicular

Genetic Tests for Follicular Lymphoma

Genetic tests related to Follicular Lymphoma:

id Genetic test Affiliating Genes
1 Follicular Lymphoma 29

Anatomical Context for Follicular Lymphoma

MalaCards organs/tissues related to Follicular Lymphoma:

39
B Cells, T Cells, Bone, Lymph Node, Bone Marrow, Skin, Breast

Publications for Follicular Lymphoma

Articles related to Follicular Lymphoma:

(show top 50) (show all 956)
id Title Authors Year
1
The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma. ( 28060738 )
2017
2
High grade follicular lymphoma in a patient receiving adalimumab and methotrexate for pityriasis rubra pilaris. ( 28266882 )
2017
3
Possible Interaction Between Cigarette Smoking and HLA-DRB1 Variation in the Risk of Follicular Lymphoma. ( 28369180 )
2017
4
Recommendations for Clinical Trial Development in Follicular Lymphoma. ( 28040699 )
2017
5
Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger. ( 27977511 )
2017
6
A case of neurolymphomatosis caused by follicular lymphoma successfully treated with bendamustine. ( 26783429 )
2016
7
Long term complication in follicular lymphoma: assessing the risk of second neoplasm in 242 patients treated or not with 90-yttrium-ibritumomab tiuxetan. ( 27157440 )
2016
8
MicroRNA expression profiling of Chinese follicular lymphoma by microarray: A preliminary study. ( 27409728 )
2016
9
Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. ( 27959929 )
2016
10
New drugs for follicular lymphoma. ( 27541051 )
2016
11
Detection of chromosomal abnormalities by G-banding and prognostic impact in follicular lymphoma in the rituximab era. ( 27995457 )
2016
12
Clinical, pathological and genetic features of follicular lymphoma grade 3A - a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. ( 27117536 )
2016
13
Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. ( 27465588 )
2016
14
Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States. ( 27124800 )
2016
15
Rituximab-induced Acute Thrombocytopenia in High Tumor Burden Follicular Lymphoma. ( 27477415 )
2016
16
Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. ( 28064239 )
2016
17
Rubinstein-Taybi syndrome - a window into follicular lymphoma biology. ( 27086936 )
2016
18
Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma. ( 27557805 )
2016
19
Low natural killer (NK) cell counts in peripheral blood adversely affect clinical outcome of patients with follicular lymphoma. ( 27518240 )
2016
20
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. ( 27418643 )
2016
21
Protocadherin I^ A3 is expressed in follicular lymphoma irrespective of BCL2 status and is associated with tumor cell growth. ( 27748813 )
2016
22
Reverse variant of follicular lymphoma: uncommon morphology in a common lymphoma. ( 28092873 )
2016
23
Safety and efficacy of Obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. ( 28011903 )
2016
24
Limited Stage Follicular Lymphoma: Current Role of Radiation Therapy. ( 27648204 )
2016
25
Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. ( 27551111 )
2016
26
miR-31 and miR-17-5p levels change during transformation of follicular lymphoma. ( 26997445 )
2016
27
Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC/BCL2 double hit lymphoma. ( 27203548 )
2016
28
Detection of Minute Duodenal Follicular Lymphoma Lesions Using Magnifying Endoscopy. ( 27094839 )
2016
29
Follicular lymphoma-related colitis resembling ulcerative colitis. ( 28013449 )
2016
30
Follicular Lymphoma Arising In a Mature Cystic Teratoma in a 26 Year Old Female. ( 27312556 )
2016
31
Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. ( 26691987 )
2016
32
Association of VEGFA-2578 C>A polymorphism with clinicopathological aspects and outcome in follicular lymphoma patients. ( 27564462 )
2016
33
The routes for transformation of follicular lymphoma. ( 27135979 )
2016
34
Integrated immunohistochemical and DNA copy number profiling analysis provides insight into the molecular pathogenesis ofA canine follicular lymphoma. ( 27135201 )
2016
35
Systematic Review on the Additional Value of 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Staging Follicular Lymphoma. ( 27560022 )
2016
36
No convincing evidence to support postinduction FDG-PET in follicular lymphoma. ( 27604230 )
2016
37
Peri-anal Paraneoplastic Pemphigus Heralding the Relapse of Follicular Lymphoma and Its Successful Management by Rituximab: A Short Correspondence. ( 27812271 )
2016
38
Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus. ( 26621338 )
2016
39
Follicular lymphoma presenting follicular papules in the skin: A case report. ( 27153936 )
2016
40
Intralesional rituximab in primary conjunctival follicular lymphoma relapsed. ( 27986437 )
2016
41
The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era. ( 27648208 )
2016
42
Epstein-Barr virus-positive follicular lymphoma. ( 27982024 )
2016
43
The clinical dilemma of grade 3 follicular lymphoma. ( 27502706 )
2016
44
Collision tumor consisting of primary follicular lymphoma and adenocarcinoma in the cecum: A case report and literature review. ( 27073555 )
2016
45
Disparities in Receipt of Radiotherapy and Survival by Age, Sex, and Ethnicity among Patient with Stage I Follicular Lymphoma. ( 27200290 )
2016
46
On the Cutoff of Baseline Total Metabolic Tumor Volume in High-Tumor-Burden Follicular Lymphoma. ( 28029314 )
2016
47
A high complex karyotype involving eleven chromosomes including three novel chromosomal aberrations and monoallelic loss of TP53 in case of follicular lymphoma transformed into B-cell lymphoblastic leukemia. ( 28031746 )
2016
48
Mitotic Index Determined by Phosphohistone H3 Immunohistochemistry for Precise Grading in Follicular Lymphoma. ( 27997502 )
2016
49
Overestimated Value of Baseline Total Metabolic Tumor Volume at (18)F-Labeled Fluorodeoxyglucose Positron Emission Tomography in Follicular Lymphoma. ( 28029311 )
2016
50
Follicular lymphoma of the caecum resected endoscopically. ( 27651135 )
2016

Variations for Follicular Lymphoma

ClinVar genetic disease variations for Follicular Lymphoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 BCL10 NM_003921.4(BCL10): c.427_428dupTT (p.Glu145Leufs) duplication Pathogenic rs587776632 GRCh37 Chromosome 1, 85733584: 85733585
2 BCL10 NM_003921.4(BCL10): c.231dupA (p.Gly78Argfs) duplication Pathogenic rs587776633 GRCh37 Chromosome 1, 85736416: 85736416
3 BCL10 NM_003921.4(BCL10): c.525_541del17 (p.Val176Asnfs) deletion Pathogenic rs587776634 GRCh37 Chromosome 1, 85733471: 85733487
4 BCL10 NM_003921.4(BCL10): c.410delA (p.Asn137Ilefs) deletion Pathogenic rs587776635 GRCh37 Chromosome 1, 85733602: 85733602
5 BCL10 NM_003921.4(BCL10): c.398dupT (p.Ser134Leufs) duplication Pathogenic rs587776636 GRCh37 Chromosome 1, 85733614: 85733614
6 BCL10 NM_003921.4(BCL10): c.635_637delAAG (p.Glu212del) deletion Pathogenic rs587776637 GRCh37 Chromosome 1, 85733375: 85733377

Copy number variations for Follicular Lymphoma from CNVD:

7 (show top 50) (show all 76)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13361 1 1 12700000 Copy number Follicular lymphoma
2 13749 1 1 27800000 Loss Follicular lymphoma
3 15761 1 119415209 120497765 Amplification NOTCH2 Follicular lymphoma
4 17512 1 143222462 153482569 Copy number ADAM15 Follicular lymphoma
5 17513 1 143222462 153482569 Copy number BCL9 Follicular lymphoma
6 17514 1 143222462 153482569 Copy number IL6R Follicular lymphoma
7 17515 1 143222462 153482569 Copy number MCL1 Follicular lymphoma
8 17516 1 143222462 153482569 Copy number PIAS3 Follicular lymphoma
9 17517 1 143222462 153482569 Copy number TNFAIP8L2 Follicular lymphoma
10 20608 1 153300000 154800000 Gain Follicular lymphoma
11 21393 1 158419998 161795584 Copy number DDR2 Follicular lymphoma
12 21394 1 158419998 161795584 Copy number PEX19 Follicular lymphoma
13 21395 1 158419998 161795584 Copy number UHMK1 Follicular lymphoma
14 25231 1 185800000 214500000 Gain Follicular lymphoma
15 54389 11 43400000 52900000 Gain Follicular lymphoma
16 61270 11 97200000 110400000 Gain Follicular lymphoma
17 65472 12 18053500 31175376 Amplification KRAS Follicular lymphoma
18 65473 12 18053500 31175376 Amplification PIK3C2G Follicular lymphoma
19 65474 12 18053500 31175376 Amplification RASSF8 Follicular lymphoma
20 65475 12 18053500 31175376 Amplification RERGL Follicular lymphoma
21 65476 12 18053500 31175376 Amplification SSPN Follicular lymphoma
22 67780 12 44600000 56300000 Gain Follicular lymphoma
23 69831 12 56316396 72147648 Copy number CDK4 Follicular lymphoma
24 69832 12 56316396 72147648 Copy number DYRK2 Follicular lymphoma
25 69833 12 56316396 72147648 Copy number FRS2 Follicular lymphoma
26 69834 12 56316396 72147648 Copy number IL22 Follicular lymphoma
27 69835 12 56316396 72147648 Copy number MDM2 Follicular lymphoma
28 69836 12 56316396 72147648 Copy number OS9 Follicular lymphoma
29 69837 12 56316396 72147648 Copy number RAB21 Follicular lymphoma
30 69838 12 56316396 72147648 Copy number RAP1B Follicular lymphoma
31 69839 12 56316396 72147648 Copy number RASSF3 Follicular lymphoma
32 69840 12 56316396 72147648 Copy number TBK1 Follicular lymphoma
33 69841 12 56316396 72147648 Copy number TSPAN31 Follicular lymphoma
34 69842 12 56316396 72147648 Copy number WIF1 Follicular lymphoma
35 69843 12 56316396 72147648 Copy number YEATS4 Follicular lymphoma
36 71140 12 67700000 71500000 Gain Follicular lymphoma
37 74580 13 109100000 114142980 Loss Follicular lymphoma
38 79541 13 73300000 79000000 Gain Follicular lymphoma
39 88260 14 88900000 106368585 Loss Follicular lymphoma
40 88262 14 88900000 106368585 Translocation Follicular lymphoma
41 92360 15 40100000 102531392 Loss Follicular lymphoma
42 97239 16 1 16700000 Gain Follicular lymphoma
43 106783 17 1 22200000 Deletion Follicular lymphoma
44 106829 17 1 24000000 Loss Follicular lymphoma
45 107553 17 15900000 22200000 Gain Follicular lymphoma
46 111280 17 35400000 47600000 Gain Follicular lymphoma
47 118113 17 7571720 7590868 Mutation P53 Follicular lymphoma
48 119191 18 1 59800000 Gain Follicular lymphoma
49 120855 18 33040900 33600413 Amplification BRUNOL4 Follicular lymphoma
50 121287 18 41800000 59800000 Translocation Follicular lymphoma

Expression for Follicular Lymphoma

LifeMap Discovery
Genes differentially expressed in tissues of Follicular Lymphoma patients vs. healthy controls: 35 (show top 50) (show all 56)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 FCRLA Fc receptor-like A Intestine + 6.40 0.000
2 SERPINA9 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 9 Intestine + 5.98 0.000
3 VPREB3 pre-B lymphocyte 3 Intestine + 5.82 0.000
4 STAG3 stromal antigen 3 Intestine + 5.61 0.000
5 SNX22 sorting nexin 22 Intestine + 5.59 0.000
6 NLRP4 NLR family, pyrin domain containing 4 Intestine + 4.89 0.004
7 LTF lactotransferrin Intestine + 4.72 0.001
8 FCER2 Fc fragment of IgE, low affinity II, receptor for (CD23) Intestine + 4.70 0.000
9 AIM2 absent in melanoma 2 Intestine + 4.66 0.000
10 P2RX5 purinergic receptor P2X, ligand gated ion channel, 5 Intestine + 4.54 0.000
11 BFSP2 beaded filament structural protein 2, phakinin Intestine + 4.33 0.000
12 DOK7 docking protein 7 Intestine + 4.29 0.000
13 KLHL14 kelch-like family member 14 Intestine + 4.26 0.000
14 GPR18 G protein-coupled receptor 18 Intestine + 4.26 0.000
15 PAX5 paired box 5 Intestine + 4.21 0.000
16 CNR1 cannabinoid receptor 1 (brain) Intestine + 4.15 0.001
17 PMCH pro-melanin-concentrating hormone Intestine + 4.09 0.000
18 AFF3 AF4/FMR2 family, member 3 Intestine + 4.02 0.000
19 MMP12 matrix metallopeptidase 12 Intestine + 3.94 0.001
20 LOC613266 uncharacterized LOC613266 Intestine + 3.92 0.000
21 C17orf99 chromosome 17 open reading frame 99 Intestine + 3.88 0.003
22 PCDHGB3 protocadherin gamma subfamily B, 3 Intestine + 3.82 0.002
23 TMEM156 transmembrane protein 156 Intestine + 3.81 0.000
24 FCRL2 Fc receptor-like 2 Intestine + 3.76 0.001
25 SCIMP SLP adaptor and CSK interacting membrane protein Intestine + 3.75 0.000
26 CCL17 chemokine (C-C motif) ligand 17 Intestine + 3.73 0.004
27 VNN2 vanin 2 Intestine + 3.71 0.000
28 OR13A1 olfactory receptor, family 13, subfamily A, member 1 Intestine + 3.59 0.001
29 PCDHGB2 protocadherin gamma subfamily B, 2 Intestine + 3.53 0.001
30 CYP4F11 cytochrome P450, family 4, subfamily F, polypeptide 11 Intestine - 3.53 0.015
31 APOBEC2 apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 2 Intestine - 3.51 0.003
32 KIAA1549L KIAA1549-like Intestine + 3.45 0.003
33 TCL6 T-cell leukemia/lymphoma 6 (non-protein coding) Intestine + 3.41 0.005
34 AFF2 AF4/FMR2 family, member 2 Intestine + 3.35 0.006
35 CD37 CD37 molecule Intestine + 3.24 0.000
36 IL22RA2 interleukin 22 receptor, alpha 2 Intestine + 3.22 0.012
37 ST6GAL1 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 Intestine + 3.22 0.001
38 ARHGAP24 Rho GTPase activating protein 24 Intestine + 3.21 0.001
39 PLEKHG7 pleckstrin homology domain containing, family G (with RhoGef domain) member 7 Intestine + 3.20 0.000
40 CAPN14 calpain 14 Intestine + 3.20 0.002
41 SPANXN3 SPANX family, member N3 Intestine - 3.18 0.002
42 TMEM155 transmembrane protein 155 Intestine + 3.16 0.002
43 RPS16P5 ribosomal protein S16 pseudogene 5 Intestine + 3.15 0.000
44 SLC7A10 solute carrier family 7 (neutral amino acid transporter light chain, asc system), member 10 Intestine + 3.15 0.002
45 SLC5A12 solute carrier family 5 (sodium/monocarboxylate cotransporter), member 12 Intestine - 3.13 0.000
46 PCDH11Y protocadherin 11 Y-linked Intestine + 3.13 0.001
47 BEND4 BEN domain containing 4 Intestine + 3.13 0.001
48 PCDHGA5 protocadherin gamma subfamily A, 5 Intestine + 3.12 0.006
49 MYBL1 v-myb avian myeloblastosis viral oncogene homolog-like 1 Intestine + 3.11 0.008
50 PDCD1 programmed cell death 1 Intestine + 3.09 0.001
Search GEO for disease gene expression data for Follicular Lymphoma.

Pathways for Follicular Lymphoma

Pathways related to Follicular Lymphoma according to GeneCards Suite gene sharing:

(show all 44)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 BCL2 BCL2L1 BCL6 CCND1 CD27 CD40
2
Show member pathways
13.11 BCL2 BCL2L1 BCL6 CCND1 CD27 CD40
3
Show member pathways
12.78 AICDA CCND1 CD40 CD80 CXCR5 TNFRSF13C
4
Show member pathways
12.73 BCL2 BCL2L1 CD27 IRF4 MCL1 MYC
5
Show member pathways
12.54 BCL2 BCL2L1 IRF4 MCL1 MYC
6 12.53 BCL2 BCL2L1 CCND1 MCL1 MYC
7
Show member pathways
12.45 BCL2 BCL2L1 CCND1 MYC
8
Show member pathways
12.36 BCL2L1 CCND1 IGH MYC
9
Show member pathways
12.35 BCL6 CR2 IRF4 MYC
10
Show member pathways
12.34 BCL2 BCL2L1 CR2 TNFRSF13C
11 12.32 BCL2L1 CCND1 CD40 MYC TNFRSF13C
12 12.26 BCL2 CD40 CR2 MYC
13
Show member pathways
12.21 BCL2 BCL2L1 CD40 CR1
14 12.19 BCL2 BCL2L1 MCL1 MYC
15 12.17 BCL2L1 BCL6 CD40 MYC
16
Show member pathways
12.04 BCL2 BCL2L1 CCND1 MCL1 MYC
17 11.9 BCL2 BCL6 CCND1 MYC
18
Show member pathways
11.85 BCL2 BCL2L1 MYC
19
Show member pathways
11.8 BCL2L1 MCL1 MYC
20
Show member pathways
11.79 CD27 CD40 TNFRSF13C
21
Show member pathways
11.78 BCL2 BCL2L1 MCL1
22 11.78 CR1 CR2 MME MS4A1
23 11.76 BCL2 BCL2L1 CD40 TNFRSF13C
24 11.74 BCL2 CCND1 MYC
25 11.73 IRF4 MME MS4A1
26 11.71 CD80 CR1 MME
27
Show member pathways
11.7 BCL2 BCL2L1 CD40
28
Show member pathways
11.66 BCL2 BCL2L1 MYC
29 11.66 BCL2 BCL2L1 CCND1 MYC
30 11.62 AICDA BCL6 IRF4
31 11.6 BCL2 CCND1 MYC
32 11.57 CD27 CD40 CD80
33 11.56 BCL2 BCL2L1 BCL6 CCND1 IRF4 MCL1
34 11.49 BCL2L1 CCND1 MYC
35 11.48 BCL6 CD40 CR1 CR2 CXCR5 TNFRSF13C
36
Show member pathways
11.41 BCL2 BCL2L1 MYC
37
Show member pathways
11.4 BCL2L1 CCND1 MYC
38
Show member pathways
11.39 BCL2 BCL2L1 MCL1
39 11.38 BCL2 BCL2L1 CCND1 MCL1
40 11.32 AICDA CD40 TNFRSF13C
41 11.29 BCL2L1 CCND1 MYC
42 10.98 BCL2 BCL2L1 MCL1
44 10.95 BCL6 CD27 CD40 CD80 CR2 CXCR5

GO Terms for Follicular Lymphoma

Cellular components related to Follicular Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.1 CD27 CD40 CD80 CXCR5 MS4A1 TNFRSF13C
2 Bcl-2 family protein complex GO:0097136 8.96 BCL2L1 MCL1

Biological processes related to Follicular Lymphoma according to GeneCards Suite gene sharing:

(show all 19)
id Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.91 BCL6 CD40 CR1 CR2 TNFRSF13C
2 negative regulation of apoptotic process GO:0043066 9.88 BCL2 BCL2L1 BCL6 CD27 MCL1 MYC
3 regulation of apoptotic process GO:0042981 9.84 BCL2 BCL2L1 BCL6 MCL1
4 viral entry into host cell GO:0046718 9.74 CD80 CR1 CR2
5 response to cytokine GO:0034097 9.67 BCL2 BCL2L1 MCL1
6 ovarian follicle development GO:0001541 9.65 BCL2 BCL2L1 MYC
7 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.61 BCL2 BCL2L1 MCL1
8 negative regulation of anoikis GO:2000811 9.58 BCL2 MCL1
9 growth GO:0040007 9.58 BCL2 BCL2L1
10 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.56 CD80 IRF4
11 regulation of mitochondrial membrane permeability GO:0046902 9.55 BCL2 BCL2L1
12 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.54 BCL2 BCL2L1 MCL1
13 complement receptor mediated signaling pathway GO:0002430 9.52 CR1 CR2
14 B cell activation GO:0042113 9.5 CD40 CXCR5 MS4A1
15 re-entry into mitotic cell cycle GO:0000320 9.46 CCND1 MYC
16 B cell differentiation GO:0030183 9.46 AICDA BCL2 BCL6 CR2
17 apoptotic mitochondrial changes GO:0008637 9.43 BCL2 BCL2L1 MCL1
18 positive regulation of B cell proliferation GO:0030890 9.26 BCL2 BCL6 CD40 TNFRSF13C
19 B cell proliferation GO:0042100 8.92 BCL2 CD40 CR2 MS4A1

Molecular functions related to Follicular Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.13 CD80 CR1 CR2
2 BH3 domain binding GO:0051434 8.8 BCL2 BCL2L1 MCL1

Sources for Follicular Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....